| Literature DB >> 32351391 |
Qian Xiang1,2, Man Wu1,2, Li Zhang1,2, Wenwei Fu1,2, Jinling Yang1,2, Baojun Zhang1,2, Zhaoqing Zheng1,2, Hong Zhang1,2, Yuanzhi Lao1,2, Hongxi Xu3.
Abstract
Mitophagy is a crucial process in controlling mitochondrial biogenesis. Balancing mitophagy and mitochondrial functions is required for maintaining cellular homeostasis. In this study, we found that Gerontoxanthone I (GeX1) and Macluraxanthone (McX), xanthone derivatives isolated from Garcinia bracteata C. Y. Wu ex Y. H. Li, induced Parkin puncta accumulation and promoted mitophagy. GeX1 and McX treatment induced the degradation of mitophagy-related proteins such as Tom20 and Tim23. GeX1 and McX directly stabilized PTEN-induced putative kinase 1 (PINK1) on the outer membrane of the mitochondria, and then recruited Parkin to mitochondria. This significantly induced phosphorylation and ubiquitination of Parkin, suggesting that GeX1 and McX mediate mitophagy through the PINK1-Parkin pathway. Transfecting ParkinS65A or pretreated MG132 abolished the induction effects of GeX1 and McX on mitophagy. Furthermore, GeX1 and McX treatment decreased cell death and the level of ROS in an ischemia/reperfusion (IR) injury model in H9c2 cells compared to a control group. Taken together, our data suggested that GeX1 and McX induce PINK1-Parkin-mediated mitophagy and attenuate myocardial IR injury in vitro.Entities:
Keywords: Gerontoxanthone I; Macluraxanthone; PINK1-Parkin pathway; ischemia/reperfusion injury; mitophagy
Year: 2020 PMID: 32351391 PMCID: PMC7175665 DOI: 10.3389/fphar.2020.00452
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1GeX1 and McX induce mitophagy. (A) HeLa cells stably expressing YFP-Parkin were treated with xanthone derivatives for 4 h. The distribution of YFP-Parkin was examined by confocal microscopy. Scale bar, 10 μm. (B) HeLa cells stably expressing YFP-Parkin were treated with GeX1 or McX for 4 h. Then we performed quantification of YFP-Parkin puncta-positive cells at different drug concentrations (10 or 20 μM), **P < 0.01, treatment with GeX1 and McX compared to DMSO. (C, D) The molecular structure of GeX1 and McX. (E) Cell proliferation after treatment with GeX1 and McX was measured in SH-SY5Y, H9c2, and YFP-Parkin HeLa cells by propidium iodide exclusion. NS, not significant.
Figure 2GeX1 and McX promote the removal of mitochondria. (A) HeLa cells were transfected with eGFP-Parkin for 24 h and then treated with GeX1 or McX (20 μM) for 6 h. The cells were stained with Tom20 (red). Representative fluorescence microscopy images were shown. The cells marked with the white solid ovals expressed no or low levels of Parkin and still had mitochondria, whereas cells marked with yellow dotted ovals expressed a high level of Parkin and had no mitochondria. (B) SH-SY5Y cells were treated with GeX1 or McX (20 μM) for 4 h. The cells were stained with MitoTracker Green and subjected to flow cytometric analysis. (C, D) SH-SY5Y cells were treated with GeX1 or McX (20 μM) at the indicated times and analyzed by western blot. Actin was used as a loading control. (E, F) SH-SY5Y cells were treated with GeX1 or McX (20 μM) for 4 h and analyzed by RT-PCR. Data for Tim23 or Tom20 mRNA levels compared with actin are shown (mean ± SEM of 3 independent experiments). NS, not significant.
Figure 3GeX1 and McX trigger Parkin phosphorylation and ubiquitination. (A) HeLa cells were transfected with GST-ParkinWT or GST-ParkinS65A mutant for 24 h and then treated with GeX1 or McX (20 μM) for 4 h. (B) The GST-ParkinS65A mutant can reverse the effects of GeX1 and McX (20 μM) on the induction of protein upregulation or downregulation. (C) YFP-Parkin HeLa cells were treated with GeX1 or McX (20 μM) for 4 h, and were then stained with anti-ubiquitin, followed by confocal microscopy. Scale bars, 10 µm. (D) YFP-Parkin HeLa cells were treated with GeX1 or McX (20 μM) for 4 h and analyzed using immunoprecipitation followed by western blotting. (E) MG132 pre-treatment for 2 h prevented GeX1 and McX (20 μM) from inducing protein increases or decreases.
Figure 4GeX1 and McX induce mitophagy in a manner dependent on PINK1. (A, B) The expression of mitophagy-related proteins follows GeX1 and McX treatment of SH-SY5Y cells. (C, D) A redistribution of mitophagy-related proteins followed GeX1 and McX (20 μM) treatment of SH-SY5Y cells. (E, F) YFP-Parkin HeLa cells were transfected with siPINK1 for 24 h and then treated with GeX1 and McX (20 μM). The distribution of YFP-Parkin was examined by confocal microscopy. Scale bars, 10 µm. NS, not significant. **P < 0.01, PINK1 knockdown YFP-Parkin HeLa cells compared to YFP-Parkin HeLa cells. (G). YFP-Parkin HeLa cells were transfected with siPINK1 for 24 h, and then treated with GeX1 and McX (20 μM). Then related proteins were analyzed by Western blot.
Figure 5GeX1 and McX attenuate IR injury in H9c2 cells. (A, B) H9c2 cells were treated with GeX1 and McX for 4, 8, 16, and 24 h, then analysed the expression of mitophagy related proteins. (C) H9c2 cells were transfected with siRNA for 48 h, then measured the expression of Parkin using western blot. (D) H9c2 cells or Parkin knockout H9c2 cells were subjected to 6 h of ischemia followed by 4 h of reoxygenation. GeX1 and McX were administered at the onset of reoxygenation. Cell proliferation was detected by propidium iodide exclusion. NS, not significant. *P < 0.05,**P < 0.01, GeX1 and McX treatment cells compared to no treatment.